New combo therapy aims to keep advanced bladder cancer at bay
NCT ID NCT07221942
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 30 times
Summary
This study tests a two-step treatment for people with advanced bladder cancer that has spread. First, patients receive a combination of two drugs (enfortumab vedotin and pembrolizumab) for 18 weeks. Then, those who respond well continue with just pembrolizumab for up to 2 years to help keep the cancer from coming back. The goal is to see if this approach improves survival without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center - Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19111-2497, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.